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the cause of  approximately two-thirds of cases of systolic HF, 
although hypertension and diabetes are probable contribut-
ing factors in many cases (3). Other causes are viral infection 
(recognized or unrecognized), alcohol abuse, chemotherapy 
(e.g., doxorubicin) and “idiopathic” dilated cardiomyopathy 
(3). Considering the high rates of hospitalization for HF and 
the ongoing  treatment and care it requires, its management 
requires a significant amount of healthcare expenditure in in-
dustrialized countries (2), with only the 30-day readmissions 
cost in the United States approximately $15 billion, so find-
ing tools to identify patients at risk and to reduce the unde-
sirable outcomes becomes a priority (4). Higher quality care 
can reduce the risk of adverse outcomes in the short term, 
as has been shown by several interventions for patients with 
HF (5). The high risk of death (ROD) or rehospitalization after 
hospitalization for HF is due to the fact that an hospitalization 
is often an expression of a state of severe HF (6), the thera-
pies are no longer effective and/or poorly tolerated and only 
a device or a transplant may improve symptoms (6, 7). The 
transition between the time in which the patient is followed 
during hospitalization to the time in which they are followed 
in the outpatient setting is a critical period because of the se-
verity of disease, the age and the likely comorbidities, and so 
proper planning of follow-up is required (8). The assessment of 
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ABSTRACT
Purpose: Heart failure (HF) is recognized as a major problem in industrialized countries. Short-term adjusted out-
comes are indicators of quality for care process during/after hospitalization. Our aim is to evaluate, for patients 
with principal diagnosis of HF, in-hospital mortality and 30-day readmissions for all-causes using two different risk 
adjustment (RA) tools.
Methods and Results: We used data from the hospital discharge abstract (HD) of a retrospective cohort of pa-
tients (2002-2007) admitted in Tuscan hospitals, Italy. Considered outcomes were in-hospital mortality and read-
mission at 30 days. We compared the All-Patients Refined Diagnosis Related Groups (APR-DRG) system and the 
Elixhauser Index (EI). Logistic regression was performed and models were compared using the C statistic (C). The 
examined records were 58.202. Crude in-hospital mortality was 9.7%. Thirty-day readmission was 5.1%. The APR-
DRG class of risk of death (ROD) was a predictive factor for in-hospital mortality; the APR-DRG class of severity 
was not significantly associated with 30-day readmissions (P>0.05). EI comorbidities which were more strongly 
associated with outcomes were nonmetastatic cancer for in-hospital mortality (odds ratio, OR 2.25, P<0.001), 
uncomplicated and complicated diabetes for 30-day hospital readmissions (OR 1.20 and 1.34, P<0.001). The dis-
criminative abilities for in-hospital mortality were sufficient for both models (C 0.67 for EI, C 0.72 for APR-DRG) 
while they were low for 30-day readmissions rate (C 0.53 and 0.52).
Conclusions: Age, gender, APR-DRG ROD and some Elixhauser comorbidities are predictive factors of outcomes; 
only the APR-DRG showed an acceptable ability to predict hospital mortality while none of them was satisfactory 
in predicting the readmissions within 30 days.
Keywords: Heart failure, In-hospital mortality, Patient readmission, Quality improvement
Introduction
Leading causes of disease burden are noncommunicable 
diseases such as cardiovascular disease. The number of people 
dying from this diseases has grown 30% since 1990 (1). Among 
cardiovascular diseases, heart failure (HF) is now recognized 
as a major and escalating public health problem in industri-
alized countries with ageing population (2). Approximately 
1-2% of the adult population in developed countries have 
HF, with a prevalence up to 10% among persons 70 years of 
age or older (2, 3). There are many causes of HF, and these 
vary in different parts of the world. Coronary artery disease is 
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 indicators of negative outcomes, such as in-hospital mortality 
and 30-day readmissions, can be used to test the quality of 
care offered; recognizing patients’ risk for these outcomes is 
a clear advantage for the improvement of health services. It is 
important that comparisons are made using risk adjustment 
(RA) tools; in fact the RA approach is a valid and useful instru-
ment for quality improvement activities (9), this continues to 
be used in reports on the quality and efficiency of the hospital, 
but is now also a frequent input for calculations of health plan, 
and is used with increasing frequency for measuring and re-
porting the performance of physicians, networks, groups and 
even individuals (10). In an increasingly competitive market for 
hospital services and health, the interest in measuring health 
outcomes has obviously grown, as they can be used as qual-
ity indicators to compare hospitals on outcomes (11-13). The 
comorbidity measures were developed to predict outcomes 
most commonly evaluated in research in hospital services—
length of stay, charges and in-hospital death (14, 15). These 
data must be risk-adjusted to create a level-playing field to 
assess the quality of interventions, regardless of differences 
attributable to the severity of the disease (10, 16). The ideal 
tool would adjust for conditions that reflect the patients’ se-
verity of illness (SOI) at admission or the natural history of the 
patients’ illness, but not adjusted for complications that could 
have been averted or ameliorated with optimal medical care 
(16). The aim of the study is to evaluate, for patients with prin-
cipal diagnosis of HF, in-hospital mortality and 30-day readmis-
sions for all-cause using two different risk adjustment tools.
Methods
Settings and data selection
We used data from the hospital discharge records (HD) of 
a retrospective cohort of HF patients (2002-2007) admitted 
in Tuscany hospitals (central Region of Italy). The inclusion 
criteria were having the principal diagnosis of HF (ICD9CM: 
428x, 398.91, 402.01, 402.11, 404.01, 404.3, 404.11, 404.13, 
4047.91, 404.93). Moreover subjects were selected on the ba-
sis of absence of other hospitalization in the previous 365 days 
for the same disease; the major diagnostic categories equal 
to 5; and age >65 years. We excluded other interventions to 
the heart and/or vessels and/or valves (ICD9CM = 35.x, 36.x, 
37.x), and did not consider resignation from spinal care unit, 
rehabilitation, long-term care and neuro-rehabilitation. Read-
missions between 0 and 1 day after discharge were consid-
ered transfers and therefore it was decided to exclude them 
from the counting of readmission. Moreover the outcomes 
considered were 1) in-hospital mortality and 2) hospital read-
mission at 30 days after discharge for all-cause.
Tools
Comorbidity measures are applicable to large administra-
tive dataset, which are now widely available at the national 
state, health plan, hospital and in some cases physician levels 
(17, 18). The tools chosen were All-Patients Refined Diag-
nosis Related Groups (APR-DRG) and Elixhauser Index (EI), 
based on administrative data. APR-DRG calculates the level of 
severity and ROD data from the index hospitalization, while 
EI calculates on the basis of all admissions of the three pre-
vious years. APR-DRG software assigns descriptors to each 
case on the SOI class and the ROD class (16). The SOI and 
ROD classes (minor, moderate, major and extreme) are deter-
mined separately based on secondary diagnosis and interac-
tions between these diagnoses and age, principal diagnoses 
and selected procedures (16). The SOI and ROD subclasses 
moreover describe the impact on the intensity of absorption 
of resources in the care process (19). The EI tool is based on 
a set of measures related to the presence of 30 comorbidity 
diagnoses obtained from the HD and DRG of last three years.
Statistical analysis
Logistic regression models were used to estimate risk-
adjusted outcome measures (20); then several significant 
predictors were incorporated in turn using odds ratio (OR). 
The performance of the models was assessed by measures 
of calibration (Hosmer-Lemeshow) and discrimination (area 
under the ROC curve). Discrimination indicates the ability 
of the model to predict a higher probability of death for 
those who actually die rather than to those who remain 
alive, while the calibration shows how the average of the 
predicted values conforms to the average of the observed 
values. The analysis was performed with STATA software 
10.0 (Data Analysis and Statistical Software, Copyright 
1996-2013 StataCorp LP). Statistical significance was set at 
P<0.05.
Results
The number of HD studied was 58,202 with 80% of pa-
tients 75 years or more. Descriptive analysis and crude OR 
in-hospital mortality and 30-day readmissions are shown in 
Table I. Crude mortality was 9.7%, lower in females and in-
creasing with age. The 30-day readmissions was 5.1%, higher 
for hospitalization longer than 10 days (OR 1.27; P≤0.001). 
In-hospital mortality, in the adjusted model, was significantly 
associated with ROD. At the highest level of ROD, extreme, 
the likely to die was 35.32 times higher than to the minor 
level. The moderate level of SOI was significantly associated 
with 30-day readmissions (OR 1.13; P = 0.006). In-hospital 
mortality with APR-DRG model showed that females are sig-
nificantly less likely to die in the hospital (OR 0.82; p<0.001) 
compared to males; increasing age is associated with a high-
er probability of in-hospital death; OR for ages 75/84 and 
85+ years was 1.47 (P<0.001) and 2.72 (P<0.001), respectively) 
(Tab. II). Among patients who are readmitted to the hospital, 
the SOI is low even in subsequent hospitalizations: 84% of pa-
tients had minor or moderate disease severity in both the in-
dex hospitalization at first readmission. Among patients with 
major or extreme severity at index hospitalization, 82% still 
has minor or moderate severity with readmission (Tab. I). Us-
ing EI, comorbidities more strongly associated with outcomes 
were nonmetastatic  cancer (OR 2.25; P<0.001) for in-hospital 
mortality and uncomplicated and complicated diabetes (OR 
1.20; P<0.001 and OR 1.34; P<0.001, respectively) for hospital 
readmission. Other characteristics associated with both in-
hospital mortality and with 30-day readmissions were gender 
(females are less likely to meet the outcomes) and  increasing 
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TABLE I - Analysis for in-hospital mortality and 30-day readmissions
In-hospital mortality No of death (%) Total (%) OR [95% Confidence interval] P value
Age (years)
 65-74 486 (4,3) 11.276 (19,4) 1
 75-84 2.154 (8,0) 26.798 (46,0) 1.94 1.75 2.15 0.001
 85+ 3.023 (15,0) 20.128 (34,6) 3.92 3.55 4.33
Gender
 M 2.591 (10,1) 25.641 (44,1) 1
 F 3.072 (9,4) 32.561 (55,9) 0.93 0.88 0.98 0.007
Days
  hospitalization <=10 days 4.410 (9,8) 44.971 (77,3) 1
  hospitalization >10 days 1.253 (9,5) 13.231 (22,7) 0.96 0.90 1.03 0.251
SOI
 Minor 1.280 (6,4) 20.002 (34,4) 1
 Moderate 2.363 (7,4) 32.011 (55,0) 1.17 1.09 1.25
 Major 1.717 (29,7) 5.781 (9,9) 6.18 5.70 6.69 0.001
 Extreme 303 (74,3) 408 (0,7) 42.21 33.57 53.07
ROD
 Minor 316 (2,6) 12.360 (21,2) 1
 Moderate 3.344 (8,7) 38.543 (66,2) 3.62 3.22 4.07
 Major 1.551 (23,8) 6.508 (11,2) 11.92 10.52 13.52 0.001
 Extreme 452 (57,1) 791 (1,4) 50.82 42.46 60.82
30-day readmissions Readmission at  
30 days (%)
Total (%) OR [95% Confidence interval] P value
Age
 65-74 509 (4,6) 10.655 (20,6) 1 .
 75-84 1.228 (4,8) 24.311 (46,9) 1.06 0.95 1.18 0.056
 85+ 910 (5,1) 16.817 (32,5) 1.14 1.02 1.27
Gender
 M 1.223 (5,1) 22.743 (43,9) 1
 F 1.424 (4,7) 29.040 (56,1) 0.91 0.84 0.98 0.015
Length of stay
  ≤10 days 1.931 (4,6) 39.967 (77,2) 1
  >10 days 716 (5,7) 11.816 (22,8) 1.27 1.16 1.39 0.001
SOI
 Minor 872 (4,5) 18.467 (35,7) 1
 Moderate 1.563 (5,1) 29.231 (56,4) 1.14 1.05 1.24
 Major 210 (5,0) 3.983 (7,7) 1.12 0.96 1.31 0.010
 Extreme 2 (1,9) 102 (0,2) 0,40 0.1 1.64
ROD
 Minor 475 (3,8) 11.904 (23,0) 1
 Moderate 1.815 (5,0) 34.676 (67,0) 1.33 1.2 1.47
 Major 335 (6,4) 4.871 (9,4) 1.78 1.54 2.05 0.001
 Extreme 22 (6,2) 332 (0,6) 1.71 1.1 2.66
age (Tab. III). APR-DRG showed to have an acceptable dis-
criminative ability on in-hospital mortality (C 0.72) while, the 
ability was inadeguate using EI (0.67). Both APR-DRG and 
EI showed to have a not satisfactory discriminative ability on 
30-day readmissions (APR-DRG C 0.52 and EI C 0.53).
Conclusion
Our study aims to make a contribution to the identifica-
tion of patients potentially at risk of early death or readmission 
 using tools that are easy and handy in an important field for 
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epidemiology, severity, cost and use of resources such as HF. 
This analysis showed that for the HF APR-DRG model predict-
able variables identified are ROD class, age, gender; in contrast 
EI model identified comorbidities as nonmetastatic cancer and 
diabetes as predictable factors for considered outcomes. An 
acceptable ability to predict hospital mortality is shown only 
for the APR-DRG of the two RA models in patients affected by 
HF, while for EI the ability to predict in-hospital mortality is a 
bit less. Readmission at 30 days for all-cause was not success-
fully predictable with APR-DRG and EI. We can therefore say 
that both models studied are good predictors for the outcome 
“in-hospital mortality”; much of the literature has confirmed 
that the APR-DRG as an RA tool for predicting mortality is ad-
equate (16, 21). The results also show that the risk of hospital 
readmission is not related to the SOI at admission. This result 
is not surprising because the readmission at 30 days seems to 
be related to factors other than the severity of the illness at 
admission such as higher rates of early follow-up (8);socioeco-
nomic factors are also associated with a higher risk of 30-day 
readmissions (22). In fact, the complexity of patients with HF, 
often elderly, with complex medical regimen and with numer-
ous comorbidities, when discharged from hospitals, requires 
early and enduring follow-ups, regardless of the class of SOI 
they belong to (8). It is also interesting to note that a multidisci-
plinary approach (geriatrician cardiologist, dietician, general HF 
education by nurse, social worker, home visits) to the patient 
with HF reduces hospital readmissions for all causes (23). Ini-
tiatives to improve the quality of care for HF should also go for 
the establishment of registers on a large scale that include the 
period from hospitalization to outpatient follow-up to detect 
and avoid unacceptable intra- and extra-hospital outcomes, 
and also to better understand the heterogeneous population 
of patients with HF, so as to guide policy decisions, guidelines 
and clinical research (7). The literature, moreover, confirms 
that the methods of risk adjustment are suitable to compare 
not only the outcomes of different therapeutic and diagnostic 
procedures but also the results produced by different hospi-
tals. It is also useful to assess the risk of a given outcome that 
could be produced from a health facility with certain charac-
teristics for patients with certain comorbidities for HF. In par-
ticular, it has recently been shown that more comprehensive 
use of diagnosis identified as present on admission improves 
the performance of mortality risk adjustment methods, and 
these improvements meaningfully change the results of hos-
pital mortality rate comparisons (24-29). A limit of this study 
is that the patients who died after discharge, at home or at a 
different hospital, were not part of mortality calculation, since 
the policy of early discharge with transfer to other hospitals of-
ten near the residence of the patients is common in Tuscany, a 
possible bias being present. Moreover the number of readmis-
sions may seem lower than the data reported in the literature; 
this may be put in relation to the characteristics of inclusion 
and exclusion of patients in the study. These choices are target-
ed to exclude patients with specific clinical features and select 
positively “new” patients for HF. In conclusion we can say that 
in the comparison between the two models both appear to be 
adequate with regard to the ROD and may therefore be useful 
for their intended purpose to measure the severity of the pa-
tients; however, the EI makes use of more data, and then gives 
more information about the patient, and is also a free tool. It is 
TABLE III -  EI model for considered outcomes. Only significant vari-
ables are shown
Elixhauser model  
In-hospital mortality
Odds  
ratio
P [95% Confidence 
interval]
Gender F 0.81 0.001 0.76 0.86
Cl age 75-84 1.95 0.001 1.76 2.16
Cl age 85+ 3.96 0.001 3.58 4.39
Hypertension uncomplicated 0.42 0.001 0.38 0.47
Neurological disorders 2.29 0.001 2.01 2.60
Chronic pulmonary disease 0.86 0.001 0.80 0.93
Diabetes uncomplicated 0.84 0.001 0.77 0.92
Diabetes complicated 0.82 0.013 0.70 0.96
Hypothyroidism 0.46 0.001 0.33 0.64
Nonmetastatic cancer 2.25 0.001 1.96 2.58
Blood loss anemia 0.48 0.001 0.36 0.64
Deficiency anemia 0.59 0.001 0.48 0.72
Depression 0.27 0.001 0.17 0.41
30-day readmissions Odds  
ratio
P [95% Confidence 
interval]
Gender F   0.9 0.005 0.82 0.96
Cl age 75-84 1.09 0.121 0.98 1.21
Cl age 85+ 1.20 0.001 1.07 1.35
Hypertension uncomplicated 0.83 0.002 0.74 0.93
Diabetes uncomplicated 1.20 0.001 1.08 1.35
Diabetes complicated 1.34 0.001 1.13 1.59
Nonmetastatic cancer 1.24 0.076 0.98 1.58
TABLE II - Adjusted APR-DRG model for considered outcomes
APR-DRG model  
In-hospital mortality
Odds  
ratio
P [95% Confidence 
interval]
Gender F 0.82 0.001 0.77 0.86
Cl age 75-84 1.47 0.001 1.32 1.63
Cl age 85+ 2.72 0.001 2.43 3.03
ROD moderate 2.34 0.001 2.06 2.65
ROD major 7.89 0.001 6.91 9.01
ROD extreme 35.32 0.001 29.36 42.50
30-day readmissions Odds  
ratio
P [95% Confidence 
interval]
Gender F 0.89 0.006 0.82 0.97
Cl age 75-84 1.07 0.214 0.96 1.19
Cl age 85+ 1.17 0.007 1.04 1.31
SOI moderate 1.13 0.006 1.03 1.23
SOI major 1.1 0.229 0.94 1.28
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important to keep looking for risk adjusted instruments able to 
predict other outcomes of interest for public health and health 
service, as indeed can be the 30-day readmissions (30). In view 
of our results, it seems appropriate that the experience with 
HF can also be tried with other pathological conditions.
Clinical implication
Because the factors that influence the possible rehospi-
talization are varied, the use of tools, that take data directly 
from the HD, can be of great importance when predicting the 
outcomes. These models must be evaluated and compared 
with each other to be useful to clinicians. Our work fits into 
that line of study that aims to evaluate these tools for risk 
stratification in order to provide clinicians with supplemen-
tal information for a better evaluation of patients’ weighted 
clinical condition. The adoption of such techniques can be 
envisaged for a multidimensional approach to patients in 
recognized risk, to improve the performance of doctors in 
preventing hospital readmissions and deaths in hospital.
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